Introduction Background Mucosal healing (MH) is an increasingly important therapeutic goal in inflammatory bowel disease. Monoclonal antibody (MA) therapy aims to achieve this and faecal calprotectin (FC) concentration has been shown as a surrogate marker for MH. Aims Our aim was to study the profile of Crohn's disease (CD) patients on MA therapy and evaluate whether FC levels after induction therapy with MA predicts the medium-term outcome. Methods Thirty-two CD patients: infliximab n = 11, adalimumab n = 21 were identified from our MA database. Data on demography and disease characteristics were extracted from case records. A subset of CD patients with FC levels measured both at baseline and after induction therapy were analysed further for response to therapy and disease course during follow-up (n = 10). Disease activity was evaluated by modified Harvey-Bradshaw index at baseline, after induction, and at 6 and 12 months during maintenance therapy. Results Of 32 patients, 22 patients were female, medium age 39.5 (range: 19-65 year), medium age at diagnosis 30.2 (range: 16-61year), mean disease duration prior to MA was 6.1 (range: 10 -22 year) and 21.8% has family history of inflammatory bowel disease. Of these, 56.2% had history of surgery prior to MA and 71.7% had concurrent immunomodulation. Disease phenotypes are shown in table. Of the 10 patients with full FC data, 6 patients normalised FC after induction (median levels 67 mg/kg, median 64 mg/ks, range 30-72). All remained in remission during follow-up median-22 months (range 13-33 months). Four patients failed to normalise FC levels with induction therapy (median 11 months, range 6-39). Of these, 2 had operation, 2 had multiple relapses (1 treated with prolonged enteral therapy and 1 with additional oral corticosteroid courses).
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are urgently needed. The aim of this study is to investigate whether essential oils (concentrated mixtures of aromatic compounds obtained by the distillation of plant tissues) have antimicrobial activity against selected gastrointestinal pathogens. Methods We have investigated the antimicrobial activity of essential oils of a wide range of culinary and medicinal herbs against type strains of selected gastrointestinal pathogens, namely Salmonella enterica, Clostridium difficile, two strains of Escherichia coli, and Candida albicans by disc diffusion assays. Grapeseed oil was the negative control. If the essential oils inhibited the growth of the organisms, a clear halo was seen around the test discs. This was measured. The experiments were performed three times and results were analysed by two sample T Tests. Essential oils were analysed by thermal desorption gas chromatography with mass spectrometry to identify the compounds present.
Results Seven of the essential oils (aniseed, asafoetida, cinnamon, clove, oregano, thyme and winter savoury) produced a strong and statistically significant inhibition of the growth of all five of the organisms tested whereas a further seven essential oils (coriander, garlic, lemon balm, lemon grass, May Chang, peppermint and rosemary) markedly inhibited the growth of three or four of the organisms (and these results were also statistically significant). Batch to batch variation was evident in the antimicrobial activity of some of the essential oils. This might correlate with variations in the profile of compounds present in the essential oils. Conclusion Some of the essential oils studied might be therapeutically useful against gastrointestinal pathogens. Quality control of the oils would be necessary and further work is needed to identify the active antimicrobial compounds in the oils. Disclosure of Interest None Declared.
